Skip to main content
Utility Menu
Investors
Newsroom
Contact Us
Regional Navigation
Global Sites
Switzerland
Deutsch
English
Français
Italiano
UK
English
United States
English
Toggle Menu Button
Utility Menu
Investors
Newsroom
Contact Us
Regional Navigation
Global Sites
Switzerland
Deutsch
English
Français
Italiano
UK
English
United States
English
Social Links
Twitter
LinkedIn
Instagram
Facebook
Main navigation
Our Disease Areas
Duchenne Muscular Dystrophy
Limb-girdle Muscular Dystrophy
Charcot-Marie-Tooth Disease
Our Science
Gene Therapy Engine
RNA Platform
Gene Editing
Manufacturing
Strategic Partnerships
Our Products & Pipeline
Products
Pipeline
Clinical Trials
Treatment Access
About Us
Leadership
Patient Affairs
Corporate Responsibility
Grants & Giving
Global Locations
Contact Us
Join Us
Career Opportunities
Toggle Menu Button
Search
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Strategic Partnerships
EU-U.S., AND SWISS-U.S. AND UK EXTENSION TO THE EU-U.S. DATA PRIVACY FRAMEWORK PRIVACY POLICY
Guardians of the last mile: Ensuring smooth delivery and a seamless patient experience
Route 79 Scholarship Program
Continuing a family legacy: Meet Sarepta colleague and Duchenne advocate Shawn Marlow
Our Pipeline
Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year
Sarepta Therapeutics anuncia los destinatarios de la 6ª edición anual de Route 79, el programa de becas de Duchenne, para el año académico 2023-2024
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pagination
First page
« First
Previous page
‹ Previous
Page
1
Page
2
Page
3
Current page
4
Page
5
Page
6
Page
7
Page
8
Page
9
…
Next page
Next ›
Last page
Last »